HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Promises Greater Innovation In Personal Care After Lackluster Q3

This article was originally published in The Rose Sheet

Executive Summary

Recent struggles cause Procter & Gamble to knock down its full-year earnings-per-share guidance. Questioned by analysts, CEO Bob McDonald accepts blame and promises that P&G “will deliver.” The firm’s U.S. grooming and oral-care businesses have taken hits due to “unprecedented” promotional spending by competitors, according to company leadership.

You may also be interested in...



CEO Lafley Defends P&G’s Long-Term Strategy, Sense Of Balance

P&G’s chief exec tells analysts that with a portfolio that creates value for consumers across the high-, mid- and lower-price product categories, the firm is well-positioned for long-term growth.

P&G Positions Beauty Biz For Share Gains, Sustainable Growth

P&G is launching multi-benefit, first-to-market skin and hair products anticipated to drive up its U.S. beauty share, CFO Moeller says at the Barclays Back to School Conference Sept. 6. Entries will include eye care under Olay Regenerist and premium-positioned hair-care items.

Demand For “Mid-Tier” Beauty Persists Despite Shrinking Middle Class

High-low pricing strategy in the mass channel is not effective for personal-care products, SymphonyIRI Group suggests, citing consumer demand for items priced in-between high-end and value-positioned items.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel